{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:39:12Z","timestamp":1781534352974,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pyoderma gangrenosum is a rare neutrophilic dermatosis that is commonly treated with systemic corticosteroids; however, their potent side effects may warrant tapering, and non\u2010steroidal systemic immunosuppressants may help maintain or bolster disease clearance during weaning. Although cyclosporine is regarded as a favorable corticosteroid\u2010sparing agent, it is associated with several side effects, such as renal toxicity and hypertension, that may limit its feasibility. Mycophenolate mofetil is a well\u2010tolerated alternative with limited data. Institutional review board approval was obtained to review patients from a single institution who received mycophenolate mofetil for pyoderma gangrenosum between January 1, 2010, and December 31, 2019. A systematic MEDLINE (PubMed) review was performed of articles containing linked keywords: \u201cmycophenolate mofetil\u201d and \u201cpyoderma gangrenosum\u201d. Patient demographics, presentation details, and treatment regimen characteristics were recorded. Fourteen of our pyoderma gangrenosum patients were treated with mycophenolate mofetil concomitantly with prednisone. Ninety\u2010three percent of our patients achieved improvement within 12\u2009months (mean 4.5\u2009months), including five patients who experienced complete healing. Outcomes in literature patients were comparable; 77% either improved or maintained clearance with mycophenolate mofetil. Greater than 80% of total patients experienced healing or adequate disease control at a median dose of 2000\u2009mg daily. The most common side effects of mycophenolate mofetil were myelosuppression and gastrointestinal upset, which were both seen in 18% of patients. Although this study is subject to publication bias, mycophenolate mofetil appears to be an efficacious and well\u2010tolerated adjunctive therapy option for pyoderma gangrenosum.<\/jats:p>","DOI":"10.1111\/ijd.15539","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T09:12:10Z","timestamp":1616145130000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-3156","authenticated-orcid":false,"given":"Matthew L.","family":"Hrin","sequence":"first","affiliation":[{"name":"Center for Dermatology Research Department of Dermatology Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun M.","family":"Bashyam","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research Department of Dermatology Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research Department of Dermatology Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research Department of Dermatology Wake Forest School of Medicine Winston\u2010Salem NC USA"},{"name":"Department of Pathology Wake Forest School of Medicine Winston\u2010Salem NC USA"},{"name":"Department of Social Sciences &amp; Health Policy Wake Forest School of Medicine Winston\u2010Salem NC USA"},{"name":"Department of Dermatology University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03199.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595240-000000000-00000"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90285-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12042"},{"key":"e_1_2_8_6_1","first-page":"l847","article-title":"Multiple eruptive ulcers in a patient with quiescent ulcerative colitis","volume":"364","author":"Tewari A","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.148113"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1509"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5978"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410020154"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072157"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.006"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.028"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00019.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.12.1546"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)70172-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63571-4"},{"key":"e_1_2_8_18_1","first-page":"689","article-title":"Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial","volume":"24","author":"Reynoso\u2010von Drateln C","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4065\/75.8.842"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1427"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.57"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03286.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06467.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3206022856"},{"key":"e_1_2_8_26_1","first-page":"326","article-title":"Treatment of pyoderma gangrenosum with methotrexate","volume":"57","author":"Teitel AD","year":"1996","journal-title":"Cutis"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1572864"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2005.00170.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.020"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.860419"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:50:37Z","timestamp":1692849037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/ijd.15539"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15539","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"2020-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}